RNXT NASDAQ
RenovoRx, Inc.
1W: -7.7%
1M: -19.4%
3M: -19.4%
YTD: -3.5%
1Y: -31.7%
3Y: -59.9%
$0.81
+0.00 (+0.52%)
After Hours: $0.83 (+0.02, +2.46%)
Weekly Expected Move ±6.8%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$30.0M
52W Range0.701-1.45
Volume271,424
Avg Volume357,213
Beta1.00
Dividend—
Analyst Ratings
Company Info
CEOShaun R. Bagai
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2021-08-26
Websiterenovorx.com
4546 El Camino Real
Mountain View, CA 94022
US
Mountain View, CA 94022
US
650 284 4433
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Latest News
RenovoRx (RNXT) Q1 2026 Earnings Transcript
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bagai Shaun | A-Award | 946,107 | $0.98 | 2026-04-03 |
| VOLL MARK | A-Award | 80,000 | — | 2026-04-03 |
| Gentry Leesa | A-Award | 128,550 | $0.98 | 2026-04-03 |
| Agah Ramtin | A-Award | 621,727 | $0.98 | 2026-04-03 |
| VOLL MARK | A-Award | 12,380 | — | 2026-03-25 |